bpc-157 typical dose mcg clinical trials dosage BPC-157 Dosing (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or Peptide Calculator - Cellgenic
Description
BLL Peptides ships all orders in plain, unmarked packaging with no reference to the contents on the outside of the package
If you feel uncertain at any point, stop and call your PlexusDx care team for guidance
Stopping treatment will make symptoms quickly resurface
Van Cauter, E., & Copinschi, G
